CRON - Cronos Group Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.86
+0.46 (+5.48%)
At close: 4:00PM EDT

9.16 +0.30 (3.39%)
Pre-Market: 7:49AM EDT

Stock chart is not supported by your current browser
Previous Close8.40
Open10.52
Bid9.11 x 3200
Ask0.00 x 2900
Day's Range8.33 - 10.55
52 Week Range6.50 - 25.10
Volume40,823,915
Avg. Volume4,612,932
Market Cap2.961B
Beta (3Y Monthly)3.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Cronos Group Issues Statement on Separately Announced IPO of Cronos Australia

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today noted the separately announced AUD$20 million initial public offering of Cronos Australia Limited (“Cronos Australia”). Under the offering, Cronos Australia is expected to issue 40 million new shares at an offering price of AUD$0.50 per share (the “Cronos Australia IPO”) ahead of its planned listing on the Australian Securities Exchange in November 2019. Established in February 2018, Cronos Australia is a 50/50 joint venture between Cronos Group and NewSouthern Capital Pty Ltd., and is led by Rodney Cocks and Peter Righetti.  The launch marked a significant milestone in Cronos Group’s commitment to advancing cannabis research and producing and distributing products and brands at a global scale.

  • GlobeNewswire

    Cronos Group Inc. to Hold Third Quarter 2019 Earnings Conference Call

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) will announce its financial results for the third quarter ended September 31, 2019 and hold its Third Quarter 2019 Earnings Conference Call on Tuesday, November 12, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.

  • GlobeNewswire

    Cronos Group Announces Appointment of Jody Begley to Board of Directors

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that, in connection with its investment in the Company, Altria Group, Inc. (“Altria”) has appointed Jody Begley to the Cronos Group Board of Directors. Mr. Begley is currently Senior Vice President, Tobacco Products for Altria Group in which he oversees more than $24 billion in net revenues.

  • GlobeNewswire

    Cronos Group Inc. CEO, Mike Gorenstein, to Present at the CIBC 18th Annual Eastern Institutional Investors Conference

    Cronos Group Inc. (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at the CIBC 18th Annual Eastern Institutional Investors Conference on Wednesday September 25, 2019 at 3:25 p.m. ET in Montreal, QC. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.

  • GlobeNewswire

    MediPharm Labs and Cronos Group Enter Private Label Contract Manufacturing Agreement

    MediPharm Labs Corp. (TSX:LABS) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has signed a multi-year contract manufacturing agreement (“CMA”) for the filling and packaging of vaporizer devices, subject to approval by Health Canada, for Cronos Group Inc.’s (CRON.TO) (CRON.TO) (“Cronos Group”) adult-use brand, COVE™. MediPharm Labs Inc. (“MediPharm”), a wholly-owned subsidiary of the Company, and a wholly-owned subsidiary of Cronos Group, entered into a CMA where MediPharm, utilizing its proprietary expertise and equipment, will provide filling of high-quality formulated concentrate, labelling and packaging services to exacting specifications at scale for Cronos Group.

  • GlobeNewswire

    Cronos Group Inc. CEO, Mike Gorenstein, to Present at Barclays 2019 Global Consumer Staples Conference

    Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos Group, will speak at Barclays Global Consumer Staples Conference at 10:30 a.m. ET in Boston, MA. The presentation will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.

  • GlobeNewswire

    Cronos Group Inc. Enters into Credit Agreement with Cronos Growing Company Inc.

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) has entered into a credit agreement (the “Credit Agreement”), as administrative agent and lender, with Cronos Growing Company Inc. (“Cronos GrowCo” or “GrowCo”), as borrower, in respect of a $100 million secured non-revolving term loan credit facility (the “Credit Facility”).

  • GlobeNewswire

    Cronos Group Inc. Announces Second Quarter and First-Half 2019 Results

    Opened Cronos Device Labs, New Global R&D Center in Israel Appointed Dr. Todd Abraham as Chief Innovation Officer Announced Agreement to Acquire.

  • GlobeNewswire

    Cronos Group Establishes New Growth Opportunity in the United States with Acquisition of Hemp-Based Products Platform

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into a definitive agreement to acquire four of Redwood Holding Group, LLC’s operating subsidiaries (collectively, “Redwood”). Redwood manufactures, markets and distributes hemp-derived cannabidiol (CBD) infused skincare and other consumer products online and through retail and hospitality partner channels in the United States under the brand, Lord Jones™. Redwood was co-founded in 2017 by Robert Rosenheck and Cindy Capobianco.

  • GlobeNewswire

    Cronos Group Enters Agreement to Acquire State-of-the-Art Fermentation and Manufacturing Facility

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation Inc. (“AFI”). As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks, Inc. (“Ginkgo”) to produce cultured cannabinoids.

  • GlobeNewswire

    Cronos Group Appoints Dr. Todd Abraham as Chief Innovation Officer

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that Dr. Todd Abraham has been appointed as the Company’s Chief Innovation Officer. In this role, Dr. Abraham will be responsible for advancing Cronos Group’s research and development initiatives in cannabinoids with a focus on identifying new disruptive technologies and adopting best practices and innovations from adjacent consumer goods industries.

  • GlobeNewswire

    Cronos Group Inc. to Hold Second Quarter 2019 Earnings Conference Call

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the second quarter ended June 30, 2019, and hold its Second Quarter 2019 Earnings Conference Call on Thursday, August 8, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.

  • GlobeNewswire

    Cronos Group Inc. Announces Results of Vote for Election of Directors

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) reports that at its Annual Meeting of Shareholders on June 19, 2019 there were 610 shareholders voting in person or by proxy holding in total 261,290,314 common shares, representing 78.2% of the total number of common shares outstanding.

  • GlobeNewswire

    Cronos Group Inc. to Present at Piper Jaffray 39th Annual Consumer Marketplace Conference, Jefferies 2019 Healthcare Conference and Stifel 2019 Cross Sector Insight Conference

    Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at three industry conferences in June. Mr. Gorenstein will present at the Piper Jaffray 39th Annual Consumer Marketplace Conference on Thursday June 6, 2019 at 1:30 p.m. ET in New York, NY, the Jefferies 2019 Healthcare Conference on Friday June 7, 2019 at 11:30 a.m. ET in New York, NY and the Stifel 2019 Cross Sector Insight Conference on Wednesday June 12, 2019 at 1:15 p.m. ET in Boston, MA. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.

  • GlobeNewswire

    Cronos Group Inc. Sets Date for 2019 Annual Meeting of Shareholders

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, will hold its 2019 Annual Meeting of Shareholders on Wednesday, June 19, 2019 at 10 a.m. ET at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto. The Notice of Meeting and Management Information Circular are available on the Governance section of the Company’s website at https://ir.thecronosgroup.com/investor-relations. A live audio webcast and replay of the meeting will also be available in the Investor Relations section of the Company’s website.

  • GlobeNewswire

    Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million

    MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.  In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.

  • GlobeNewswire

    Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.

  • GlobeNewswire

    Cronos Group Inc. Announces First Quarter 2019 Results

    Cronos Group Closes C$2.4 Billion Strategic Investment from Altria Group Cronos Group Establishes Cronos Device Labs, a State-of-the-Art Vaporizer R&D Initiative NatuEra.

  • GlobeNewswire

    Cronos Group Opens Cronos Device Labs, New Global R&D Center in Israel

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it is expanding its global infrastructure network and innovation capabilities with the opening of a cannabinoid device R&D facility, based in Israel (“Cronos Device Labs”). The state-of-the-art facility supports Cronos Group’s efforts to develop next-generation vaporizer products that are designed specifically for cannabinoid applications. Cronos Device Labs, which is equipped with an experienced team of product development talent, advanced vaporizer technology and analytical testing infrastructure, serves as the global center of R&D for the Company’s vaporizer devices.

  • ACCESSWIRE

    Company with Solution for Indoor Growers Reporting Big Losses

    One company we've highlighted in the past CleanSpark, Inc. (CLSK) has developed power solution for the cannabis industry that can reduce energy costs by up to 82%. This represents a huge potential revenue stream for the company. Due to this fact the company has stated that marketing to cannabis companies is one of their top initiatives for 2019.

  • CNW Group

    North America is a Pace Setter for the Burgeoning Cannabis Industry

    NEW YORK, April 18, 2019 /CNW/ -- The tremendous growth of the cannabis market is causing the marketspace to become an emerging global industry. Under international regulations, cannabis is one of the most heavily enforced drugs, primarily due to the psychoactive effects of marijuana. The marijuana plant is comprised primarily of THC, which causes the psychoactive effects.

  • ACCESSWIRE

    Don't Overlook Energy When Investing in Cannabis

    One industry that is often overlooked but could play a huge role in the cannabis industry is energy. The U.S. cannabis industry is currently eating up more than 1% of all electricity each year. The need to reduce greenhouse emissions created by the weed industry, as well as lower electric load and expenditures, makes the energy sector a clear beneficiary of a budding cannabis industry.

  • CNW Group

    Hemp Boom Spawns Lucrative Deals

    DENVER, April 17, 2019 /CNW/ -- Ever since the Farm Bill was signed into law, farmers across the United States have rushed into hemp cultivation, driving demand for the supplies needed to grow the crop necessary to meet surging CBD use. Global hemp industry to reach $22 billion in 2022. Hemp is booming across the country, and nowhere more so than in Kentucky, where the applications to grow hemp are expected to increase fivefold, and acreage dedicated to growing the crop is set to more than triple this year.

  • CNW Group

    Growth in Cannabis Remains Strong in North America as Companies Expand

    NEW YORK, April 15, 2019 /CNW/ -- Canada moved to legalize cannabis entirely in late 2018, however, cannabis-based companies remain more attracted to the U.S. market. Despite not having legalized cannabis entirely, the U.S. market is one of the most attractive marketplaces for cannabis companies and investors. Many of these Canadian-based cannabis companies are beginning to establish operations in the U.S., particularly in large markets such as California, Colorado, and Nevada.

  • CNW Group

    Mainstream Acceptance, Strong Growth Adds to Growing CBD Market

    DENVER, April 11, 2019 /CNW/ -- The CBD market is experiencing explosive growth as a result of growing mainstream acceptance and strong leadership. The North American CBD market, worth more than $9 billion in 2017, is projected to be worth $47 billion by 2027. Growth is possible partly through mainstream acceptance, with pressure on a variety of institutions to accept medical CBD.